ignated 1 orphan drug in 1983, 70 in 2000, and 199 in 2011. In the EU, the EMA designated 10 orphan drugs in 2000 (f rst year of designations) and 104 in 2011 (www.fda. gov and www.ema.europa.eu, respectively; a single drug may have an orphan designation for more than one indication). T ree areas within orphan diseases have the most orphan drug approvals: pediatric indications, rare types of cancer, and genetic diseases. Protein replacement therapies have proven to be a valuable treatment for rare monogenic diseases.
T e f rst monogenic protein replacement therapies (MPRTs) in the orphan drug space to receive regulatory approval in the United States and EU were blood factors and enzyme replacement therapies for lysosomal storage disorders. T ese MPRTs introduced a new commercial model called "orphan drug pricing, " in which high premiums are applied to life-changing therapies. Currently, the annual cost for MPRTs, such as Fabrazyme, Elaprase, and Naglazyme, generally exceeds $200,000 (1) , and sales of orphan MPRTs exceed $100 million per year.
T ere has been considerable attention given to the high prices of orphan drugs and the challenges with reimbursement (2, 3) . MPRTs are reimbursed in the United States, in many countries of the EU, and in Japan, and they are of en supplied at no cost in the developing world or through patient assistance programs. In order to continue to support orphan drug pricing and obtain reimbursement, it is important for developers of MPRTs to make a case to payers for cost-ef ectiveness of these therapies. Although certain MPRTs have shown longterm safety, clinical ef cacy, and improvements in health-related quality of life (4-6), more data are needed to demonstrate costef ectiveness (a net reduction in health-care costs from MPRTs) to justify reimbursement in certain countries (2) .
LOW DEVELOPMENT RISK
T e Tuf s Center for the Study of Drug Development (CSDD) has published several reports on clinical approval success rates. In 2010, DiMasi et al. published the results of a study evaluating the clinical approval success rates for investigational compounds that entered clinical testing between the mid-1990s and the early 2000s from the 50 largest pharmaceutical f rms (as determined by 2006 sales) (7) . T is study stratif ed data by product type (large versus small molecule). T e authors reported the overall probability of clinical approval success at 19%, with biologic drugs having a higher success rate (32%) than that of smallmolecule drugs (13%). Tu% s CSDD also published a report in 2010 that looked specif cally at approval probabilities for orphan drugs. In this study, sponsors engaged in orphan grant-funded development reported that 22% of their clinical programs led to approvals (8) . T e probability of regulatory approval for MPRTs, which comprise only a small fraction of the total number of approved drugs, has not been determined.
We conducted an analysis to determine whether MPRTs would have a higher probability of success through clinical trials, compared with all orphan drugs and all other drug classes. If these therapies have a higher probability of success than those of other new molecular entities (NMEs), a case could be made for expanded investment to develop MPRTs for orphan diseases that currently have no approved therapeutic products.
MPRT: APPROVED OR TERMINATED?
To conduct our analysis, we consulted several data sources. We began by reviewing all U.S. and EU orphan product designations and identifying monogenic protein replacement therapy candidates (www.fda.gov and www.ema.europa.eu). Because companies may not seek orphan designations for certain protein replacement therapies (for example, follow-on therapies or plasmaderived therapies reviewed at the national level in the EU), we supplemented our orphan drug designated product search by conducting candidate searches in the Adis R&D Insight database (http://bi.adisinsight. com), reviewing public domain candidate data from Tu% s CSDD (http://csdd.tu% s. edu/research/databases), reviewing product listings from the World Federation of Hemophilia (www.wf .org), and by reviewing the pipelines of companies we know are active in the MPRT space. Our analyses were restricted to MPRTs for the treatment of orphan diseases that had entered or completed clinical trials, f led for or received regulatory approval as of 30 November 2011. For inclusion in the study group, therapies had to meet certain criteria, as described in the Supplementary Methods.
We identif ed 144 replacement therapies approved or investigated for 40 unique proteins that are def cient or dysfunctional owing to mutations in a single gene associated with an orphan disease ( orphan drugs (8) .
[T e probability of regulatory approval for monogenic protein replacement therapies of 88% was calculated as follows: (85 × 100) / (85 + 11).] To reduce the inf uence of the large number of approved candidates for Factor VIII and Factor IX, we also calculated the probability of approval for a f rst-in-class protein replacement therapy. Here, we considered the number of targets that had at least one approved MPRT (21 targets) with the total number of targets for which a candidates' ultimate fate (approval or termination) was known (23 targets). Only two targets, arylsulphatase A and porphobilinogen deaminase, had candidates terminated in clinical trials, with no approved therapies (table S1). T us, f rst-in-class MPRTs have a 91% probability of regulatory success.
BLOOD FACTORS AND LYSOSOMAL ENZYMES DOMINATE
If we consider the 27 targets from Table 1 that have active clinical stage and/or approved programs, 85% of MPRTs to these targets can be classif ed as blood components (12 targets) or lysosomal enzymes (11 targets). T e remaining 15% of MPRTs are targeted to metabolic disorders. T ese target classes may represent the "low-hanging fruit, " and the >85% probability of regulatory success for MPRTs is high because the clinical pathogenesis, mechanism of action, and ability to manufacture the MPRT are well understood for blood components and many lysosomal enzymes. It is possible that the probability of regulatory success of MPRTs for targets outside of these classes will decrease with challenging targets, such as structural proteins, or di& cult methods of delivery, such as for central nervous system disorders.
Similarly, lysosomal enzymes and blood products make up 78% of the identif ed preclinical programs (18/23), with 22% (5 programs) directed toward targets outside of these classes. New MPRT preclinical targets include structural proteins in dermatology (collagen VII in dystrophic epidermolysis bullosa and ectodysplasin-A1 in X-linked hypohidrotic ectodermal dysplasia), mitochondrial enzymes (thymidine phosphorylase in mitochondrial neurogastrointestinal encephalopathy and frataxin in Friedreich's ataxia), and a nonlysosomal metabolic enzyme [lecithin-cholesterol acyltransferase (LCAT) in LCAT def ciency]. Paul et al. (10) developed an R&D model to estimate the cost of discovering and developing a single new molecular entity from lead discovery through preclinical and clinical studies to commercial launch. If the high (88%) probability of clinical success for MPRTs was used in this model, it would substantially reduce the out-of-pocket costs and total capitalized costs for the clinical development of an MPRT, compared with small molecules and other biologics.
CLINICAL AND COST ADVANTAGES

OPPORTUNITIES REMAIN
T e commercial potential of MPRTs and the unmet need for new drugs for orphan diseases has led to increasing attention from the pharmaceutical and biotechnology industries, as well as from the investment community owing to the potential returns within this sector. Several companies that focused on the development and commercialization of MPRTs have been acquired for large sums. For instance, in 2011 Sanof -Aventis acquired Genzyme for ~$20 billion, and Alexion acquired Enobia for ~$1.1 billion.
T ere are many monogenic diseases that do not have approved protein replacement therapies. Federal agencies such as the National Institutes of Health and the FDA have developed specif c guidelines to accelerate regulatory approval and provide incentives for orphan drug development. In addition to the commercial success of MPRTs, we hope the observation that MPRTs demonstrate a high probability of regulatory approval will provide another incentive to develop additional MPRTs for diseases for which no therapy is available, as well as to create improved follow-ons for existing treatments. Methods  Table S1 . Active MPRT preclinical candidates and MPRTs that have entered clinical development or received regulatory approval.
SUPPLEMENTARY MATERIALS
